NCT02563093View on ClinicalTrials.gov

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

July 31, 2016

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative

0.5 mL, Intramuscular (IM)

BIOLOGICAL

Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation

0.1 mL, Intradermal

BIOLOGICAL

Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone High-Dose vaccine, 2015-2016 formulation

0.5 mL, Intramuscular

Trial Locations (4)

45249

Cincinnati

51503

Council Bluffs

70006

Metairie

95405

Santa Rosa

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02563093 - Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults | Biotech Hunter | Biotech Hunter